We have previously reported the inhibition of bacterial topoisomerase I activity by a 25 fluoroquinophenoxazine compound (FP-11g) with a 6-bipiperidinyl lipophilic side chain that 26 exhibited promising antituberculosis activity (MIC = 2.5 µM against Mycobacterium 27 tuberculosis, SI = 9.8). Here, we found that the compound is bactericidal towards 28
Introduction 44
Tuberculosis (TB) is a devastating disease caused by Mycobacterium tuberculosis 45 infection. The World Health Organization (WHO) reported that TB is the leading cause of death 46 worldwide from a single infectious agent. The 2018 Global Tuberculosis Report estimated that 47 TB caused ~1.6 million deaths in 2017, with up to 10 million newly diagnosed TB cases 48 annually [1] . Significantly, drug-resistant TB poses a great threat to public health. In 2017, there 49 were 558,000 new cases of drug resistant TB, including multidrug resistant TB (MDR-TB). 50 resistant to rifampicin and isoniazid (two first-line anti-TB drugs) and rifampicin-resistant TB 51 (RR-TB) [1] . These TB patients are more likely to have poor treatment outcomes. Therefore, 52 there is an urgent need for potent new TB drugs with novel modes of action [2] . Resistance to 53 current antibiotics also makes it difficult to treat infections caused by nontuberculous 54 mycobacteria (NTM) . It is often difficult to distinguish between M. tuberculosis and NTM as 55 the cause of lung infections, so there is a medical need for new antibiotics that have broad 56 antimycobacterial activity. 57 DNA topoisomerases are essential enzymes for maintaining optimal DNA topology to 58 facilitate vital functions including replication, transcription, recombination and DNA repair [3] . 59
Topoisomerases belong to type I or type II families corresponding to cleavage of a single or 60 double strand of DNA being utilized for catalysis [4] with subfamilies based on sequence 61 homology and mechanism [5] . Every bacterium has at least one type IA topoisomerase for 62 overcoming topological barriers that require cutting and rejoining of a single strand of DNA [3, 63 6 ]. Topoisomerase I catalytic activity is essential for the viability of Mycobacterium smegmatis 64 (Msm) and M. tuberculosis (Mtb) [7, 8] , because these organisms only have one type IA 65 topoisomerase. Mtb topoisomerase I (MtbTopI) is a validated anti-TB target; [7, 9, 10] for 66 identification of inhibitors that can potentially be developed into leads for new TB therapy. 67
We have previously shown [11] that a fluoroquinophenoxazine compound 68 shown in Scheme 1) with a 6-bipiperidinyl lipophilic side chain inhibited the catalytic activity of 69 Escherichia coli topoisomerase I (IC50 = 0.48 µM), and showed promising antituberculosis 70 activity (MIC = 2.5 µM against Mtb H37Rv, SI = 9.8 for Vero cell cytotoxicity). In this study, 71
we followed up on the antimycobacterial activity of this compound to further explore its 72 therapeutic potential. The interactions of this compound with MtbTopI and DNA were 73 characterized in biophysical assays. Mechanism of resistance to its antimycobacterial activity 74 was studied with M. smegmatis. This commonly used model mycobacterial organism is non-75 pathogenic and fast growing, but still shares many features with pathogenic mycobacteria. 76 77
Materials and Methods

78
Synthesis of FP-11g 79 FP-11g (Scheme 1) was synthesized using our previously reported procedure [11] . The structure 80 was confirmed by 1 H NMR, and high-resolution mass spectrometry (HRMS). Purity was 81 determined to be >99% by reverse phase C18-HPLC. 82 83 MIC (minimum inhibitory concentration) against M. smegmatis and M. abscessus 84 M. smegmatis mc2 155 (WT from ATCC) and FP-11g resistant mutants derived from WT were 85 cultured in 5 ml Middlebrook 7H9 broth containing 0.2% glycerol, 0.05% Tween 80 with or 86 without a supplement of 10% albumin, dextrose, sodium chloride (ADN) at 37°C with shaking. 87
Stationary phase bacteria cultures were adjusted to an optical density (OD600) of 0.1 and 88 subsequently diluted 1:10 using growth media. Fifty microliters (~10 5 cfu) of the diluted culture 89 were transferred to the individual wells of a clear round-bottom 96-well plate containing 50 μl of 90 serially diluted compounds. The 96-well plate was then incubated at 37°C with shaking. After 48 91 hours of incubation, resazurin (final concentration 0.002%) was added to the individual wells 92 and the fluorescence reading at 560/590 nm was taken with a BioTek Synergy plate reader after 93 approximately 5h of incubation at 37°C. 94
A clinical isolate of M. abscessus bacterium (isolated at the Columbia University Medical 95 Center) was cultured in Middlebrook 7H9 ADN broth till it reached an optical density (OD600) of 96 1.0. The culture was stored at -80°C as 1 ml aliquots containing 15% glycerol. These frozen 97 aliquots were then used as the inoculum for M. abscessus MIC assays. Prior to conducting each 98 MIC assay, an aliquot of frozen M. abscessus was thawed and diluted 1:100 in Middlebrook 7H9 99 broth. After dilution, the bacterial cells (~10 5 cfu) were added to the wells of a 96-well plate 100 containing the serially diluted compounds as described for M. smegmatis cells and incubated at 101 37°C with no shaking for 48 h. Subsequently, resazurin (final concentration 0.005%) was added 102 to each well and fluorescence reading at 560/590 nm (excitation/emission) was taken after 24 h 103 of incubation at 37°C. MIC was determined as compound concentration that showed at least 90% 104 reduction in fluorescence when compared to the control (no inhibitor) wells. Ciprofloxacin and 105
Clarithromycin were included in the assay as positive controls. On the day of each MIC assay, 106 thawed inoculum of M. abscessus was also serially diluted and spread plated on LB agar plates 107 to confirm for the inoculum load of ~10 5 cfu/well. MIC determination for each bacteria was 108 repeated at least three times. 109 110
Survival assays 111
The bactericidal effect of FP-11g compound was evaluated in 96-well plates using a protocol 112 similar to the MIC assay. In brief, M. smegmatis was incubated at 37°C with shaking in the 113 presence of 1X, 2X, 4X and 8X MIC of FP-11g for 6, 10, 24 and 48 hours; M. abscessus was 114 incubated at 37°C without shaking in the presence of 1X and 2X MIC of FP-11g for 24, 48 and 115 72 hours. At each time point 20 µl from the treatment wells were serially diluted (10 fold), 116 spread on LB agar plates and incubated at 37°C for 4 or 7 days for counting the viable colonies 117 of M. smegmatis and M. abscessus respectively. Ten microliters from the treatment wells were 118 also enriched in 5-ml of Middlebrook 7H9 broth if there are no viable colonies from a particular 119 treatment-time combination on the LB agar plates. The survival percentage was calculated by 120 dividing the number of viable colonies at each time point by the initial viable count prior to the 121 treatment (time 0). Survival assays were repeated three times. 122 123
Isolation of resistant mutants 124
M. smegmatis mc2 155 was exposed stepwise to increasing concentrations of FP-11g to isolate 125 mutant strains with different levels of resistance for FP-11g by a slightly modified protocol as 126 described by Fujimoto-Nakamura et al [12] . Overnight culture of M. smegmatis was adjusted 127 to an optical density (OD600) of 0.1 and a volume of 100 µl (2x10 6 cfu) was spread on 7H9 ADN 128 agar containing 2.5 μM (8X MIC) FP-11g for isolation of resistant mutants. Colonies appearing 129 on these plates were scored as resistant mutants only if they grew again on 7H9 ADN broth and 130 agar plates containing 8X MIC of FP-11g. Mutation frequency was calculated based on these 131 resistant colonies. Only one resistant mutant was isolated at 8X MIC of FP-11g. This resistant 132 mutant was next exposed to 16X MIC of FP-11g in 7H9 ADN broth to further isolate resistant 133 colonies PGM1, PGM2 shown in Table 1 . As our initial resistant mutation isolation at 8X MIC 134 of FP-11g resulted in only one mutant, a second round of stepwise mutation was initiated with 135 4X MIC to higher concentrations of FP-11g (PGM3 -PGM6 shown in Table 1 ). 136 This mix was loaded in the pre-thawed reagent cartridge associated with the MiSeq Reagent kit 151 v3 and sequenced using Illumina MiSeq® Next Generation Sequencer. FASTQ files generated 152 from the sequencing run was further analyzed in CLC genomics workbench 10 software 153 (QIAGEN). Sequence of M. smegmatis mc2 155 WT strain from our laboratory was used as 154 reference to compare all the mutant sequences and detect variations (Single Nucleotide 155
Variations, Deletions and Insertions). 156
MtbTopI relaxation inhibition assay -MtbTopI was expressed in E. coli T7 Express crystal strain 159 (New England Biolabs) and purified as previously described [13, 14] . The relaxation activity of 160
MtbTopI was assayed in a buffer containing 10 mM Tris-HCl, pH 8.0, 50 mM NaCl, 0.1 mg/ml 161 gelatin, and 0.5 mM MgCl2. Serial dilutions of FP-11g dissolved in DMSO was mixed with 10 μl 162 of the reaction buffer containing 12.5 ng of enzyme before the addition of 9 μl of reaction buffer 163 containing 160 ng of supercoiled pBAD/Thio plasmid DNA purified by cesium chloride gradient 164 as the substrate. The reactions were terminated following an incubation of the mixtures at 37°C 
Dialysis experiments 205
Dialysis assays were carried out according to the previously published procedure [15] . Briefly, a 206 volume of 0.3 ml of 75 μM (bp) of ST DNA was pipetted into a 0.3 ml disposable dialyzer. The 207 dialysis units were then placed into a beaker with 100 ml of 1×BPE buffer (6 mM Na2HPO4, 2 208 mM NaH2PO4, and 1 mM EDTA, pH 7) containing 1 µM of FP-11g. The dialysis was allowed to 209 equilibrate with continuous stirring for 72 hours at room temperature (24°C). After the dialysis, 210 the free, bound, and total concentrations of FP-11g were determined spectrophotometrically. The MIC of FP-11g for M. smegmatis mc2 155 was found to be 0.31 μM in multiple 225 measurements. The MIC value is the same in 7H9 media with or without ADN supplement. 226 There is also no effect on the MIC from shaking during the incubation. For the clinical M. 227 abscessus isolate, the MIC was 50 μM, compared to Clarithromycin MIC of 0.7-1.56 μg/ml (1-2 228 μM) and Ciprofloxacin MIC of 12.5 μg /ml (38 μM), IC50 for 50% growth inhibition of the M. 229 abscessus strain was estimated to be 3-6 μM. 230 231 Bactericidal activity of FP-11g 232 FP-11g showed strong bactericidal activity against M. smegmatis. When M. smegmatis cells 233 (~1x10 5 cells in each well in 96-well plate) were exposed to 2X MIC of FP-11g, the cell viability 234 was diminished by ~ 4.5 Log after 48 hours of incubation ( Fig 1A) . For concentrations of 4X 235 MIC and 8X MIC, 24 hours were sufficient to diminish cell viability by greater than 5 Log, with 236 no viable cells remaining at 48 hours. 237
Treatment of M. abscessus with 2X MIC of FP-11g resulted in >3 Log loss of cell 238 viability ( Fig 1B) . The M. abscessus strain grows slower than M. smegmatis, so treatment was 239 extended to 72 hours. Because of the higher MIC value for M. abscessus, FP-11g concentrations 240 could only be tested at up to 4X MIC in the survival assay. 241 
Isolation and verification of resistant mutants 252
The mutation frequency for resistance to FP-11g at 8X (MIC) was estimated to be 5x10 -7 . Six 253 M. smegmatis strains (PGM1 -PGM6, Table 1 ) isolated from stepwise increase of FP-11g 254 concentrations were verified to be resistant to the compound by determination of MIC. An 255 increase in the resistance to Moxifloxacin was also observed but the fold-increase in 256
Moxifloxacin was significantly lower than the fold-increase for FP-11g MIC. 257 258
Mutations identified in WGS 259
The mutations found in each of the resistant strains are listed in Table 2 . Mutations in ten 260 different genes associated with deletions, insertions or SNV (Single Nucleotide Variations) were 261 detected in these mutants ( Table S1 ). All of the resistant strains have SNV on MSMEG_0965 262 gene (mspA), which codes for the major porin in M. smegmatis. This porin is important for the 263 permeation of nutrients and antibiotics inside the cell. Previous studies showed that the deletion 264 of this gene in M. smegmatis resulted in a reduced permeability to drugs such as β-lactams, 265 fluoroquinolones and chloramphenicol [17] [18] [19] [20] . The mspA gene is present in fast-growing 266 mycobacteria only, and is not found in M. tuberculosis [21, 22] . 267
The second most frequent mutation (in 3 out of 6 mutants) detected corresponds to 268 
Comparison of inhibition of MtbTopI versus DNA gyrase 290
The IC50 of FP-11g for inhibition of E. coli topoisomerase I relaxation activity has been reported 291 as 0.48 µM [11] . In comparison, the IC50s for inhibition of human topoisomerase I relaxation 292 activity and topoisomerase IIα decatenation activity were found to be both around 3.9 µM in the 293 previous report [11] . Here we determined the IC50 for inhibition of MtbTopI and Mtb DNA 294 gyrase by FP-11g (Fig 2) . The IC50 for MtbTopI (0.24 µM) is ~100-fold lower than the IC50 for 295 inhibition of Mtb DNA gyrase (31 µM). 296 FP-11g has a pronounced induced visible band around 330 nm with a maximum absorbance at 317 334 nm. Binding of FP-11g to DNA also causes a red shift to the fluorescence emission spectrum 318 of FP-11g ( Fig 4B) . The fluorescence intensity is slightly enhanced upon binding to DNA. Table  319 3 summarizes the optical properties of free and DNA-bound FP-11g. 320 Fig 4C shows the DNA UV melting profiles in which different concentrations of FP-11g 321 were added to the same concentration of ST DNA. In the absence of FP-11g, the UV melting 322 temperature of ST DNA (Tm) was determined to be 70.8 o C. In the presence of saturated FP-11g 323 (40 µM), the DNA UV melting temperature was increased to 81.9 o C, indicating that FP-11g 324 tightly binds to ST DNA. In this study, we also carried out a dialysis binding assay in which 75 325 µM (bp) ST DNA was extensively dialyzed against a large excess of 1 µM of FP-11g. Fig 4D  326 shows our results. After 72 hours of dialysis, the concentration of FP-11g outside the dialysis bag 327 was not significantly changed. In contrast, the concentration of FP-11g inside the dialysis bag 328 where the ST DNA was located was increased to 25 µM. The DNA binding constant of FP-11g 329 was estimated to be 1x10 6 M -1 in 1XBPE. these structures in these organisms [22] . The mutation in MspA porin is likely to be the first 372 mechanism of resistance developed by M. smegmatis, and hence the common mutation was 373 found. Changes in the porin may interrupt the drug transportation into the cell and support cell 374 survival. Since this porin is present in fast growing mycobacteria, it would be of significance in 375 the treatment of atypical pathogenic mycobacteria including M. abscessus studied here [30] . 376
Characterization of integral membrane proteins has been always a challenge due to the 377 difficulty for the expression, solubility and crystallization of these proteins. Most of the 378 information has been obtained through computational approaches, which predict the structural 379 conformation of a protein based on the primary sequence and classify the different types of 380 transmembrane proteins [31, 32] . Transmembrane proteins could be associated with 381 mechanisms of resistance to drugs that are not targeting them directly. Integral component of 382 membrane are channels through the cellular membrane that transport amino acids, lipids, 383 coenzymes, carbohydrates, nucleotides and other metabolites [33] . Mutations in integral 384 membrane proteins detected here may affect drug transportation through the membrane. 385
Variation in channels that transport molecules through the cell wall will affect the intake of 386 molecules including drugs and metabolites. These integral components of membrane could also 387 be non-characterized efflux pumps that may be extruding the drug from the organism and 388 support the drug resistance. 389
In this study we detected the MmpL11 mutation in two resistant mutants. Previous 390 studies with M. tuberculosis strains harboring mutations in MmpL proteins showed that all of the 391 mutant strains retained general drug susceptibility to diverse antibacterial agents. This suggests 392 that MmpL proteins do not play a direct role in drug resistance [34] . Nonetheless, recent studies 393 have shown that the extended RND permease superfamily in M. tuberculosis include both RND 394 multidrug efflux transporters and members of the MmpL family [35] . In M. abscessus, MmpL 395 has been associated with drug resistance through efflux pumps [36] . Additionally, mutations on 396
MmpL11 proteins has been associated with impairment of biofilm formation in M. smegmatis. 397
The absence of this gene has generated a reduced permeability to antimicrobial agents [37, 38] , 398 which is evidence that this mutation may play an important role in FP-11g resistance. 399
Remarkably, we did not detect mutations in the topA gene in the resistant mutant isolates. 400
This might be due to FP-11g acting as an unconventional catalytic inhibitor. These types of 401 inhibitors are described as compounds that bind to the DNA as well as to the topoisomerase 402 enzyme to inhibit the topoisomerase activity [39] . Mutations that affect the essential activity of 403 topoisomerase I could compromise cell growth to a significant extent and would less likely be 404 selected for resistance than the mutations detected here that can limit compound transport into 405 the cell. It is also possible that due to its interaction with DNA, FP-11g inhibits multiple DNA 406 binding proteins in its mode of action, including DNA gyrase as observed here. Further studies 407 are required to identify other analogs of FP-11g that can be more selective in targeting 408 topoisomerase I activity in its antimycobacterial mechanism of action. This would require 409 Figure 5 
